At least one anti-B7-H3 monoclonal antibody has already been developed, enoblituzumab, which showed potent antitumor activity by peripheral blood mononuclear cells towards B7-H3-expressing tumors [55,57] and has been recently clinically tested in a phase I trial for solid pediatric tumors, including neuroblastoma (www.clinicaltrials.gov: NCT02982941, accessed on 21 April 2021). Here, CD276 is linked to neuroblastoma.